BAM
VNDA icon

Belpointe Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Belpointe Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-21
Closed -$143 – 3303
2023
Q1 		$143 Buy
+21
New +$148 ﹤0.01% 3699

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Belpointe Asset Management's VNDA Position: Q2 2023 in Review

Belpointe Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2023, closing a stake of 21 shares — an estimated $143 sold.

Belpointe Asset Management first reported a position in VNDA in Q1 2023 and held it in 1 quarter. The position peaked at $143 in Q1 2023. 188 funds tracked by Wall St. Rank hold VNDA as of Q2 2023.

  • Belpointe Asset Management reported no remaining Vanda Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 21 Vanda Pharmaceuticals shares in Q2 2023, an estimated $143.
  • Belpointe Asset Management first reported a position in Vanda Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Vanda Pharmaceuticals position peaked at $143 in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.